Delivery Order SPE2DR25D9239-SPE2DR26FFBY7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $87,418.08 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xenpozyme 20 mg vials. The contract was awarded on September 4, 2025, with an ultimate completion date of September 25, 2025, and utilizes firm fixed-price pricing with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $87,418.08 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xenpozyme 20 mg vials. This firm fixed-price delivery order, issued on August 13, 2025, with an ultimate completion date of September 4, 2025, represents a continuation of the companies' established partnership. The award was made without a set-aside designation, allowing DMS...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $109,272.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XENPOZYME 20 MG VIALS, a specialized pharmaceutical product, with a period of performance through November 6, 2024. DMS Pharmaceutical Group is a key supplier for the DLA, holding a $499,999,999 Indefinite Delivery Contract to...
- The Defense Logistics Agency awarded a $87.4K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xenpozyme 20 mg vials. The contract is a firm fixed-price delivery order with an ultimate completion date of October 1, 2025, and was awarded on September 10, 2025. This award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its small...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on June 18, 2025, by the Defense Logistics Agency (DLA) for the supply of Xenpozyme 20 mg vials. This firm fixed-price delivery order, valued at $87,418.08, is due for completion by July 11, 2025, and represents the supply of a specialized pharmaceutical product to support Department of Defense healthcare operations. The award was issued without a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on August 29, 2025, for the supply of Xenpozyme 20 mg vials. This firm fixed-price delivery order, valued at $87,418.08, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency...
- The Defense Logistics Agency awarded a delivery order valued at $201,718.80 to DMS Pharmaceutical Group Inc. for the supply of Xenpozyme 20 mg vials. This firm fixed-price delivery order, issued on September 29, 2025, is expected to be completed by October 21, 2025, with fulfillment occurring at the contractor's facility in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on equal footing despite its status as a woman-owned small...
- The Defense Logistics Agency awarded a $253,772.90 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Xenpozyme 20 mg vials, with an ultimate completion date of October 20, 2025. This delivery order, issued on September 28, 2025, carries no set-aside designation and represents work to be performed in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois and registered in the System for Award Management...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $109,272.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of XENPOZYME 20 MG VIALS and has an ultimate completion date of April 15, 2024. This delivery order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract with DLA, contract 4600082013 under the SPE2DB program, which is valued at up...
- The U.S. Defense Logistics Agency awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of XENPOZYME 20 mg vials. The $109,272.60 contract has a completion date of March 19, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler based in Park Ridge, Illinois that provides a wide range of branded and generic drugs to government agencies, particularly the Department of Veterans Affairs and Department of...
- SPE2DR25D9239Indefinite Delivery Contract
- SPE2DR25D9239-SPE2DR26FFBY7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $70,393.68 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xenpozyme 20 mg vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of February 12, 2026, and carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) within the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to consolidate pharmaceutical sourcing across the Department of Defense. DMS Pharmaceutical Group has demonstrated substantial capability as a critical pharmaceutical supplier to the federal military medical system, with its IDC ceiling valued at $499,999,999 extending through December 31, 2036. The company's established performance across numerous delivery orders spanning oncology treatments, specialty pharmaceuticals, biologics, and medical consumables positions it as a key provider within the Defense Logistics Agency's Medical Supply Chain division. As the sole prime contractor on this award with no identified subcontractors, DMS Pharmaceutical Group continues to leverage its small business status and comprehensive product portfolio to support Department of Defense healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $70.4k | 1/21/26 |